A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
This study is testing new drug combinations, centered around an investigational medication called ONC201, for children and young adults with aggressive brain or spinal cord tumors known as diffuse midline gliomas. Because these tumors are very difficult to treat and current options are limited, researchers are working hard to find more effective therapies.
Children and young adults who have been newly diagnosed with these specific types of brain or spinal cord tumors, or whose tumors have returned after previous treatments like radiation, may be able to join. Eligibility depends on the exact location of the tumor, genetic features, and your past treatment history.
Participants will receive a combination of treatments, which may include the study drug ONC201 along with other targeted medications, experimental therapies, or radiation therapy depending on their specific study group. The study uses a flexible design to add promising new treatments as research progresses.
This study is currently recruiting patients and takes place at medical centers in locations including Birmingham, Alabama, as well as Los Angeles and San Diego, California.
- 1Tests combination therapies including the investigational drug ONC201 for difficult brain tumors.
- 2Open to children and young adults with newly diagnosed or returning diffuse midline gliomas.
- 3Currently recruiting participants at select medical centers in Alabama and California.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.